Literature DB >> 26773602

Roles of phosphodiesterases in the regulation of the cardiac cyclic nucleotide cross-talk signaling network.

Claire Y Zhao1, Joseph L Greenstein2, Raimond L Winslow3.   

Abstract

The balanced signaling between the two cyclic nucleotides (cNs) cAMP and cGMP plays a critical role in regulating cardiac contractility. Their degradation is controlled by distinctly regulated phosphodiesterase isoenzymes (PDEs), which in turn are also regulated by these cNs. As a result, PDEs facilitate communication between the β-adrenergic and Nitric Oxide (NO)/cGMP/Protein Kinase G (PKG) signaling pathways, which regulate the synthesis of cAMP and cGMP respectively. The phenomena in which the cAMP and cGMP pathways influence the dynamics of each other are collectively referred to as cN cross-talk. However, the cross-talk response and the individual roles of each PDE isoenzyme in shaping this response remain to be fully characterized. We have developed a computational model of the cN cross-talk network that mechanistically integrates the β-adrenergic and NO/cGMP/PKG pathways via regulation of PDEs by both cNs. The individual model components and the integrated network model replicate experimentally observed activation-response relationships and temporal dynamics. The model predicts that, due to compensatory interactions between PDEs, NO stimulation in the presence of sub-maximal β-adrenergic stimulation results in an increase in cytosolic cAMP accumulation and corresponding increases in PKA-I and PKA-II activation; however, the potentiation is small in magnitude compared to that of NO activation of the NO/cGMP/PKG pathway. In a reciprocal manner, β-adrenergic stimulation in the presence of sub-maximal NO stimulation results in modest cGMP elevation and corresponding increase in PKG activation. In addition, we demonstrate that PDE2 hydrolyzes increasing amounts of cAMP with increasing levels of β-adrenergic stimulation, and hydrolyzes increasing amounts of cGMP with decreasing levels of NO stimulation. Finally, we show that PDE2 compensates for inhibition of PDE5 both in terms of cGMP and cAMP dynamics, leading to cGMP elevation and increased PKG activation, while maintaining whole-cell β-adrenergic responses similar to that prior to PDE5 inhibition. By defining and quantifying reactions comprising cN cross-talk, the model characterizes the cross-talk response and reveals the underlying mechanisms of PDEs in this non-linear, tightly-coupled reaction system.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cardiac myocytes; Computational model; Cyclic nucleotide cross-talk signaling network; NO/cGMP/PKG pathway; Phosphodiesterases; β-adrenergic pathway

Mesh:

Substances:

Year:  2016        PMID: 26773602      PMCID: PMC4764497          DOI: 10.1016/j.yjmcc.2016.01.004

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  105 in total

1.  Cyclic nucleotide research -- still expanding after half a century.

Authors:  Joseph A Beavo; Laurence L Brunton
Journal:  Nat Rev Mol Cell Biol       Date:  2002-09       Impact factor: 94.444

2.  cGMP-cAMP interplay in cardiac myocytes: a local affair with far-reaching consequences for heart function.

Authors:  Alessandra Stangherlin; Manuela Zaccolo
Journal:  Biochem Soc Trans       Date:  2012-02       Impact factor: 5.407

Review 3.  AKAPs: the architectural underpinnings of local cAMP signaling.

Authors:  Michael D Kritzer; Jinliang Li; Kimberly Dodge-Kafka; Michael S Kapiloff
Journal:  J Mol Cell Cardiol       Date:  2011-05-11       Impact factor: 5.000

4.  Modeling of biopterin-dependent pathways of eNOS for nitric oxide and superoxide production.

Authors:  Saptarshi Kar; Mahendra Kavdia
Journal:  Free Radic Biol Med       Date:  2011-07-08       Impact factor: 7.376

5.  Differential expression of PDE5 in failing and nonfailing human myocardium.

Authors:  Xiaoyin Shan; Michael P Quaile; Jeffery K Monk; Benjamin French; Thomas P Cappola; Kenneth B Margulies
Journal:  Circ Heart Fail       Date:  2011-12-01       Impact factor: 8.790

Review 6.  Regulation of cardiac remodeling by nitric oxide: focus on cardiac myocyte hypertrophy and apoptosis.

Authors:  Kai C Wollert; Helmut Drexler
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

Review 7.  Nitric oxide and excitation-contraction coupling.

Authors:  Joshua M Hare
Journal:  J Mol Cell Cardiol       Date:  2003-07       Impact factor: 5.000

8.  Single L-type Ca(2+) channel regulation by cGMP-dependent protein kinase type I in adult cardiomyocytes from PKG I transgenic mice.

Authors:  Frank Schröder; Gunnar Klein; Beate Fiedler; Michaela Bastein; Nicole Schnasse; Anja Hillmer; Sandra Ames; Stepan Gambaryan; Helmut Drexler; Ulrich Walter; Suzanne M Lohmann; Kai C Wollert
Journal:  Cardiovasc Res       Date:  2003-11-01       Impact factor: 10.787

Review 9.  What is the role of beta-adrenergic signaling in heart failure?

Authors:  Martin J Lohse; Stefan Engelhardt; Thomas Eschenhagen
Journal:  Circ Res       Date:  2003-11-14       Impact factor: 17.367

Review 10.  Modulation of cardiac contraction, relaxation and rate by the endothelial nitric oxide synthase (eNOS): lessons from genetically modified mice.

Authors:  P B Massion; J-L Balligand
Journal:  J Physiol       Date:  2003-01-01       Impact factor: 5.182

View more
  20 in total

1.  Cross-regulation of Phosphodiesterase 1 and Phosphodiesterase 2 Activities Controls Dopamine-mediated Striatal α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Trafficking.

Authors:  Roy S Song; Rosa Tolentino; Eric A Sobie; Susana R Neves-Zaph
Journal:  J Biol Chem       Date:  2016-09-07       Impact factor: 5.157

2.  Mechanisms of the cyclic nucleotide cross-talk signaling network in cardiac L-type calcium channel regulation.

Authors:  Claire Y Zhao; Joseph L Greenstein; Raimond L Winslow
Journal:  J Mol Cell Cardiol       Date:  2017-03-29       Impact factor: 5.000

3.  Dysregulation of Neuronal Ca2+ Channel Linked to Heightened Sympathetic Phenotype in Prohypertensive States.

Authors:  Hege E Larsen; Emma N Bardsley; Konstantinos Lefkimmiatis; David J Paterson
Journal:  J Neurosci       Date:  2016-08-17       Impact factor: 6.167

Review 4.  Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease.

Authors:  Grace E Kim; David A Kass
Journal:  Handb Exp Pharmacol       Date:  2017

Review 5.  Therapeutic Targeting of PDEs and PI3K in Heart Failure with Preserved Ejection Fraction (HFpEF).

Authors:  Valentina Sala; Jean Piero Margaria; Alessandra Murabito; Fulvio Morello; Alessandra Ghigo; Emilio Hirsch
Journal:  Curr Heart Fail Rep       Date:  2017-06

Review 6.  Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure.

Authors:  Rima Kamel; Jérôme Leroy; Grégoire Vandecasteele; Rodolphe Fischmeister
Journal:  Nat Rev Cardiol       Date:  2022-09-01       Impact factor: 49.421

Review 7.  Cyclic GMP and PKG Signaling in Heart Failure.

Authors:  Genri Numata; Eiki Takimoto
Journal:  Front Pharmacol       Date:  2022-04-11       Impact factor: 5.988

Review 8.  Phosphodiesterase type 5 and cancers: progress and challenges.

Authors:  Ines Barone; Cinzia Giordano; Daniela Bonofiglio; Sebastiano Andò; Stefania Catalano
Journal:  Oncotarget       Date:  2017-10-12

9.  Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes.

Authors:  Csaba Mátyás; Balázs T Németh; Attila Oláh; Marianna Török; Mihály Ruppert; Dalma Kellermayer; Bálint A Barta; Gábor Szabó; Gábor Kökény; Eszter M Horváth; Beáta Bódi; Zoltán Papp; Béla Merkely; Tamás Radovits
Journal:  Eur J Heart Fail       Date:  2016-12-19       Impact factor: 15.534

Review 10.  Imaging of PDE2- and PDE3-Mediated cGMP-to-cAMP Cross-Talk in Cardiomyocytes.

Authors:  Nikoleta Pavlaki; Viacheslav O Nikolaev
Journal:  J Cardiovasc Dev Dis       Date:  2018-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.